Home page Home page

Mirapexin
pramipexole

Package leaflet: Information for the user


MIRAPEXIN 0.088 mg tablets MIRAPEXIN 0.18 mg tablets MIRAPEXIN 0.35 mg tablets MIRAPEXIN 0.7 mg tablets Pramipexole


Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.

sweating or pain may occur (called dopamine agonist withdrawal syndrome or DAWS).


Tell your doctor if you experience any of these behaviors; he will discuss ways of managing or reducing the symptoms.


For the side effects marked with * a precise frequency estimation is not possible, since these side effects were not observed in clinical studies among 1,395 patients treated with pramipexole. The frequency category is probably not greater than “uncommon”.


Reporting of side effects

image

If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via thenationalreportingsystem listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.

  1. How to store MIRAPEXIN


    Keep this medicine out of the sight and reach of children.


    Do not use this medicine after the expiry date which is stated on the carton after EXP. The expiry date refers to the last day of that month.


    Do not store above 30°C.

    Store in the original package to protect the tablets from light.


    Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.


  2. Contents of the pack and other information What MIRAPEXIN contains

The active substance is pramipexole.


Each tablet contains 0.088 mg, 0.18 mg, 0.35 mg, or 0.7 mg pramipexole as 0.125 mg, 0.25 mg,

0.5 mg, or 1 mg pramipexole dihydrochloride monohydrate, respectively.


The other ingredients are mannitol, maize starch, anhydrous colloidal silica, povidone K 25 and magnesium stearate.


What MIRAPEXIN looks like and contents of the pack

MIRAPEXIN 0.088 mg tablets are white, of round shape, flat, and without scoring.


MIRAPEXIN 0.18 mg tablets and MIRAPEXIN 0.35 mg tablets are white, of oval shape, and flat. Tablets are scored on both sides and breakable in halves.


MIRAPEXIN 0.7 mg tablets are white, of round shape, and flat. Tablets are scored on both sides and breakable in halves.


All tablets have the Boehringer Ingelheim company symbol embossed on one side and the codes P6, P7, P8, or P9 on the other side, representing the tablet strengths 0.088 mg, 0.18 mg, 0.35 mg, and

0.7 mg, respectively.


All strengths of MIRAPEXIN are available in aluminium blister strips of 10 tablets per strip, in cartons containing 3 or 10 blister strips (30 or 100 tablets). Not all pack sizes may be marketed.


Marketing Authorisation Holder


Boehringer Ingelheim International GmbH D-55216 Ingelheim am Rhein

Germany


Manufacturer


Boehringer Ingelheim Pharma GmbH & Co. KG D-55216 Ingelheim am Rhein

Germany

image

Boehringer Ingelheim France 100-104 avenue de France 75013 Paris

France

For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:


België/Belgique/Belgien

SCS Boehringer Ingelheim Comm.V

Tél/Tel: +32 2 773 33 11

Lietuva

Boehringer Ingelheim RCV GmbH & Co KG

Lietuvos filialas

Tel: +370 5 2595942


България

Бьорингер Ингелхайм РЦВ ГмбХ и Ко. КГ -

клон България

Тел: +359 2 958 79 98

Luxembourg/Luxemburg

SCS Boehringer Ingelheim Comm.V

Tél/Tel: +32 2 773 33 11


Česká republika

Boehringer Ingelheim spol. s r.o.

Tel: +420 234 655 111

Magyarország

Boehringer Ingelheim RCV GmbH & Co KG

Magyarországi Fióktelepe Tel: +36 1 299 89 00


Danmark

Boehringer Ingelheim Danmark A/S

Tlf: +45 39 15 88 88

Malta

Boehringer Ingelheim Ireland Ltd.

Tel: +353 1 295 9620


Deutschland

BIOTHERAX biochemisch-pharmazeutische Gesellschaft mbH

Tel: +49 (0) 800 77 90 900

Nederland

Boehringer Ingelheim b.v. Tel: +31 (0) 800 22 55 889


Eesti

Boehringer Ingelheim RCV GmbH & Co KG

Eesti filiaal

Tel: +372 612 8000

Norge

Boehringer Ingelheim Norway KS

Tlf: +47 66 76 13 00


Ελλάδα

Boehringer Ingelheim Ellas A.E.

Tηλ: +30 2 10 89 06 300

Österreich

Boehringer Ingelheim RCV GmbH & Co KG

Tel: +43 1 80 105-7870


España

Boehringer Ingelheim España, S.A. Tel: +34 93 404 51 00

Polska

Boehringer Ingelheim Sp.zo.o. Tel: +48 22 699 0 699


France

Boehringer Ingelheim France S.A.S.

Tél: +33 3 26 50 45 33

Portugal

Boehringer Ingelheim Portugal, Lda.

Tel: +351 21 313 53 00


Hrvatska

Boehringer Ingelheim Zagreb d.o.o. Tel: +385 1 2444 600

România

Boehringer Ingelheim RCV GmbH & Co KG Viena - Sucursala Bucureşti

Tel: +40 21 302 28 00


Ireland

Boehringer Ingelheim Ireland Ltd. Tel: +353 1 295 9620

Slovenija

Boehringer Ingelheim RCV GmbH & Co KG Podružnica Ljubljana

Tel: +386 1 586 40 00

Ísland

Vistor hf.

Sími: +354 535 7000

Slovenská republika

Boehringer Ingelheim RCV GmbH & Co KG organizačná zložka

Tel: +421 2 5810 1211


Italia

Boehringer Ingelheim Italia S.p.A.

Tel: +39 02 5355 1

Suomi/Finland

Boehringer Ingelheim Finland Ky

Puh/Tel: +358 10 3102 800


Κύπρος

Boehringer Ingelheim Ellas A.E. Tηλ: +30 2 10 89 06 300

Sverige

Boehringer Ingelheim AB Tel: +46 8 721 21 00


Latvija

Boehringer Ingelheim RCV GmbH & Co KG

Latvijas filiāle

Tel: +371 67 240 011

United Kingdom (Northern Ireland)

Boehringer Ingelheim Ireland Ltd.

Tel: +353 1 295 9620


This leaflet was last revised in {MM/YYYY}.